File:2GQG Abl1Kinase<unk> .Crystal structure ( PDB 2GQG) of Abl kinase domain (blue) in complex with<unk>  (red).<unk>  is an ATP-competitive protein tyrosine kinase inhibitor. The main targets of<unk>  are BCR/Abl (the "Philadelphia chromosome"), Src, c-Kit, ephrin receptors, and several other tyrosine kinases. Strong inhibition of the activated BCR-ABL kinase distinguishes<unk>  from other CML treatments, such as imatinib and nilotinib. Although<unk>  only has a plasma half-life of three to five hours, the strong binding to BCR-ABL1 results in a longer duration of action.
Dasatinib
Neratinib
Tucatinib
Imatinib
Lapatinib
Ponatinib
Fostamatinib
Capmatinib